Only one other drug, atuveciclib (PTEFb/CDK9 inhibitor) (Supplementary Figure 3), was identified as significantly more effective in basal cell lines of drugs with and average DSS3 > 10 for basal bladder cancer, while 4 individual MEK inhibitors are significantly more effective in basal bladder cell lines, using the same criteria. Here, CDK9 is linked to urinary bladder carcinoma.